Moderna, Inc. (MRNA)
Moderna, Inc. reported revenue of $1.94B for the fiscal year ended Dec 31, 2025, down 39.9% from $3.24B the year before. Net income was a loss of $2.82B, a net margin of -145.2% (prior year: −$3.56B). At the end of that fiscal year the company reported total assets of $12.34B and shareholders' equity of $8.65B.
Revenue
$1.94B
−39.9% vs prior year
Net income
−$2.82B
Net margin -145.2%
Diluted EPS
−$7.26
USD per share
Total assets
$12.34B
At Dec 31, 2025
Equity
$8.65B
At Dec 31, 2025
Shares outstanding
399M
As of Jul 24, 2026
Explore Moderna, Inc.'s filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Jul 31, 2026
- 10-QFiled May 1, 2026
- 10-KFiled Feb 20, 2026
- 10-QFiled Nov 6, 2025
- 10-QFiled Aug 1, 2025
- 10-QFiled May 1, 2025
Source: SEC EDGAR XBRL company facts for CIK 1682852 (raw data). Most recent filing in this dataset: 10-Q filed Jul 31, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.